Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4146 Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

Introduction: Limited therapeutic options are available for patients with advanced neuroendocrine neoplasms (NENs). Cabozantinib (CBZ), a tyrosine kinase inhibitor including c-MET pathway, and Temozolomide (TMZ), an alkylating agent enhancing the anti-angiogenic effect of CBZ, are emerging as promising treatments in NENs.

Conference:

Presenting Author:

Authors: Tornesello M, Starita N, Clemente O, Cerasuolo A, Bracigliano A,

Keywords: cabozantinib, temozolomide, neuroendocrine tumor, cell lines, in vitro study,

#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus

Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Albertelli M, Mohamed A, Arvigo M, Grillo F, Barbieri F,

Keywords: neuroendocrine, primary cultures, drugs,

#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.

Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: Albertelli M, Mohamed A, Marica A, Grillo F, Barbieri F,

Keywords: neuroendocrine, primary cultures, drugs,

#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study

Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Faggiano A, Ferolla P, Dicitore A, Castiglioni S, Borghi M,

Keywords: medullary thyroid cancer, neuroendocrine tumor, RAD001, Everolimus, octreotide, antitumor activity,